R. Nolan Townsend

R. Nolan Townsend is a seasoned executive currently serving as the Chief Executive Officer of Lexeo Therapeutics since January 2020. " " " " His appointment as CEO marked a new chapter after a substantial career at Pfizer, where he held various roles from 2008 to December 2019, culminating as President of Pfizer Rare Disease for the North America region. " " " "

Prior to his current role, he built a strong foundation in the pharmaceutical industry, demonstrating expertise in strategy, cross-functional leadership, and operational management. His work at Pfizer and subsequent leadership at Lexeo reflect his dedication to advancing biopharmaceutical innovations. " " " "

In addition to his executive responsibilities, he holds board positions at Arbor Biotechnologies and the Biotechnology Innovation Organization. His academic credentials, including a B.A. in Economics from the University of Pennsylvania and an M.B.A. from Harvard Business School, further complement his extensive professional experience. " " " "

Option Awards

• Grant Date: August 22, 2023 " " "
• Number of Shares: 106,472 " " "
• Exercise Price: $11.02 per share " " "
• Grant Date Fair Value: $8.27 per share " " "
• Grant Date Stock Price: $11.02 per share " " "
• Vesting Schedule: 25% of the shares vest on August 22, 2024 with the remaining shares vesting in equal monthly installments over the following 36 months contingent on continuous service " " "
• Performance Metrics & Targets: No specific performance metrics, targets, or thresholds provided " " "

Non-Equity Incentive Plan Compensation

• Amount: $347,880 "
• Target Bonus: 55% of annual base salary ($575,000 as of October 1, 2023) "
• Performance Metrics & Targets: No further performance criteria or detailed performance metrics provided "